News
U.S. drugmaker AbbVie Inc will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's cancer drug, the companies said on Friday.
ROCKVILLE, MD, and SHANGHAI, China, July 10, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative ...
I-Mab, a late-stage cancer/autoimmune biotech developing in-licensed antibodies in China, raised $104 million by offering 7.4 million ADSs at $14, within the range of $12 to $15. I-Mab plans to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results